Subject
Infectious Diseases,Pharmacology (medical),Microbiology (medical)
Reference9 articles.
1. Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI);Solomkin;Clin Infect Dis,2015
2. In vitro activity of ceftolozane/tazobactam against phenotypically defined extended-spectrum β-lactamase (ESBL)-positive isolates of Escherichia coli and Klebsiella pneumoniae isolated from hospitalized patients (SMART 2016);Karlowsky;Diagn Microbiol Infect Dis,2020
3. The efficacy and safety of tazobactam/ceftolozane in combination with metronidazole in Japanese patients with complicated intra-abdominal infections;Mikamo;J Infect Chemother,2019
4. Pharmaceutical safety and environmental health bureau, Ministry of health, labour and Welfare. Guideline for the clinical evaluation of antibitotis;Pharmaceutical Evaluation Division;PFSD/ELD Notification No.,2017
5. Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections;Lucasti;Antimicrob Agents Chemother,2014